

Outsmarting Shape-Shifting Lung Cancer Resistance

Written by The Life Science Feed Editorial Team · Published 30 May 2026 · Edited by Sarah Mitchell

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Mok TS et al. AURA3: osimertinib vs platinum-based chemotherapy in T790M NSCLC. N Engl J Med. 2017;376:629-640
2. Soria JC et al. FLAURA: osimertinib vs first-generation EGFR TKI. N Engl J Med. 2018;378:113-125
3. Planchard D et al. FLAURA2: osimertinib plus chemotherapy vs osimertinib in EGFR-mutant NSCLC. N Engl J Med. 2023;389:1935-1948
4. Yu HA et al. Mechanisms of acquired resistance to first-generation EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2013;19:2240-2247
5. Niederst MJ et al. RB loss in resistant EGFR mutant lung adenocarcinomas. Nat Commun. 2015;6:6377

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com